Home/Pipeline/Camrelizumab (SHR-1210)

Camrelizumab (SHR-1210)

Multiple cancer types

ApprovedCommercial

Key Facts

Indication

Multiple cancer types

Phase

Approved

Status

Commercial

Company

Jiangsu Hengrui Medicine

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd. is a leading Chinese pharmaceutical company founded in 1970, headquartered in Lianyungang, Jiangsu Province. The company has evolved from producing generic drugs to becoming a major innovator in oncology, with particular strength in developing novel cancer treatments, anesthesia drugs, and medical imaging contrast agents. Hengrui has established itself as one of China's most valuable pharmaceutical companies with significant R&D investments and an expanding global footprint.

View full company profile

Therapeutic Areas

Oncology Anesthesia Contrast Imaging Pain Management Hematology

Other Multiple cancer types Drugs

Drug	Company	Phase	Status
BNT327	BioNTech	Phase 2/3	Active
Keytruda (pembrolizumab)	Merck	Commercial	Active
Opdivo (nivolumab)	Bristol Myers Squibb	Commercial	Approved
LENVIMA (lenvatinib)	Eisai	Commercial	Approved